GlassScriptPhysician profile
Allyson L Kirk
NPI 1407852973
$4,526.46
in general payments reported to CMS, 2019-2025
26 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $812 · 2023: $967 · 2024: $1,050 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,087.08 | 2021-2025 | Dupixent |
| Amgen INC. | $627.64 | 2021-2025 | Tezspire, Repatha, Actimmune |
| Astrazeneca Pharmaceuticals LP | $627.22 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $600.39 | 2022-2025 | |
| Csl Behring | $283.45 | 2021-2025 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $236.00 | 2022-2025 | Cuvitru, Takhzyro, Hyqvia |
| Biocryst US Sales Co., LLC | $232.77 | 2022-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $122.57 | 2025 | |
| Kaleo, INC. | $91.52 | 2021-2024 | Auvi-Q |
| Optinose US, INC. | $70.45 | 2021-2024 | |
| Glaxosmithkline, LLC. | $68.75 | 2021-2022 | |
| Genentech USA, INC. | $56.93 | 2023-2025 | Xolair |
| Lilly USA, LLC | $44.13 | 2024-2025 | Ebglyss |
| Incyte Corporation | $40.49 | 2022-2023 | Opzelura |
| Uswm, LLC | $40.34 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.72 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $37.70 | 2025 | Neffy |
| Pfizer INC. | $36.95 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.76 | 2022 | |
| Pharming Healthcare, INC. | $27.20 | 2024 | Ruconest |
| Octapharma USA, INC. | $25.29 | 2025 | Panzyga |
| Alk-Abello, INC | $22.89 | 2023 | Ragwitek, Grastek, Odactra |
| Grifols USA, LLC | $22.55 | 2024 | Xembify |
| Ionis Pharmaceuticals, INC. | $20.45 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $15.13 | 2022 | |
| Covis Pharma Gmbh | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.